Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement
|Articles|October 1, 2017

PE 2017 AAM Statement

Advertisement
External Link - Pharm-Exec-2017-statement.pdf

Advertisement

Related Content

Advertisement
stock.adobe.com pharma finance

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report

ByNicholas Jacobus
August 26th 2026
Pharmaceutical Executive Daily

Pharmaceutical Executive Daily: Haisco Licenses Preclinical Immunology Asset to Sentivera

ByNicholas Jacobus
August 26th 2026
The FDA approved daraxonrasib (Rasonque), the first RAS-directed therapy for previously treated metastatic pancreatic adenocarcinoma, after a phase 3 trial showed median overall survival of 13.2 months versus 6.7 months with chemotherapy. Credit: Stock.Adobe.com/Sebastian Kaulitzki

FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer

ByPharmExec Staff
August 26th 2026
Stock.Adobe.com drug costs

Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report

ByNicholas Jacobus
August 26th 2026
licensing deal adobe.com/stock

Licensing Roundup: Biohaven & SK Biopharmaceuticals Enter Deal for BHV-7000, Haisco License’s Sentivera Lead Immunology Asset

ByNicholas Jacobus
August 26th 2026
Advertisement
Advertisement

Trending on PharmExec

1

M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership

2

Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report

3

FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer

4

The Retailization of Medicare Advantage: What Costco’s Entry Means for Pharma

5

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us